Testosterone replacement therapy (TRT) improves potency recovery following robot-assisted radical prostatectomy (RARP), investigators reported at the 34th Annual European Association of Urology Congress in Barcelona, Spain.
Farouk M. El-Khatib, MD, and colleagues from the University of California, Irvine, studied 442 men undergoing RARP who had a preoperative International Index of Erectile Function (IIEF-5) score of 22 to 25, free testosterone values below 5.1 ng/dL collected prospectively before RARP, and responses to Erections Sufficient for Intercourse questionnaires at 3 and 24 months.
Of the 442 men, 49 (11.1%) were never on TRT and 13 (2.9%) were on TRT within 1 year of surgery. Among men who received TRT within 1 year, 6 (46.2%) and 13 (100%) were potent at 3 and 24 months, respectively. Of the men who never received TRT, 30 (61.2%) and 41 (83.7%) were potent at 3 and 24 months, respectively.
“TRT was predictive of increased return of potency post-RARP, all patients on TRT fully recovered at 24 months,” the authors concluded in their study abstract. “Men should be counseled about the risk of impotency and considered for perioperative TRT for faster potency recovery.”
El-Khatib FM, Huynh L, Towe M, et al. Testosterone replacement therapy improves potency recovery following robot assisted radical prostatectomy. Presented at the 34th Annual European Association of Urology Congress in Barcelona Spain, March 15-19. Abstract 1067.